Giuseppe Marino, Serena Negri, Filippo Testa, Daniela Giuliani, Elena De Ponti, Martina Bombelli, Pecis Cavagna Giorgia, Daniele Lugotti, Marta Jaconi, Alessandra Casiraghi, Tommaso Bianchi, Tommaso Grassi, Maria Cristina Bonazzi, Robert Fruscio
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
UO Gynecology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Gynecol Oncol Rep. 2025 Mar 11;58:101715. doi: 10.1016/j.gore.2025.101715. eCollection 2025 Apr.
Immature teratomas represent rare malignant ovarian germ cell tumours, typically involving young women The majority of germ cell tumors (60%-70%) are diagnosed at an early stage, showing an optimal prognosis. However, advanced stages represent about one third of these patients. We report the oncologic outcome of this population, investigating also fertility outcomes in patients who underwent fertility preservation.
Clinicopathological data were retrospectively collected and analysed from a cohort of 17 post-pubertal patients with advanced stage immature teratomas in a single centre between 1980 and 2024.
Among 17 patients included in the study, 76.5 % (13/17) underwent fertility-sparing surgery (FSS) and 23.5 % (4/17) radical surgery. Adjuvant chemotherapy was administered in 82 % (14/17) of patients. After a median follow up of 237 months (range 68.0-289.0), 2 patients had persistent disease after receiving chemotherapy and 3 showed relapse. Of these, two had a second relapse. All patients are alive without evidence of disease at the last follow up. Also 46 % (6/13) of women treated with FSS reached pregnancy.
FSS appears to be safe and effective in the treatment of advanced stage immature teratoma. Despite surgical interventions and the administration of chemotherapy in the majority of patients, fertility outcome is satisfactory.
未成熟畸胎瘤是一种罕见的恶性卵巢生殖细胞肿瘤,多见于年轻女性。大多数生殖细胞肿瘤(60%-70%)在早期被诊断出来,预后良好。然而,晚期患者约占这些患者的三分之一。我们报告了这一人群的肿瘤学结局,并对接受生育力保存的患者的生育结局进行了研究。
回顾性收集并分析了1980年至2024年间在单一中心的17例青春期后晚期未成熟畸胎瘤患者的临床病理数据。
在纳入研究的17例患者中,76.5%(13/17)接受了保留生育功能手术(FSS),23.5%(4/17)接受了根治性手术。82%(14/17)的患者接受了辅助化疗。中位随访237个月(范围68.0-289.0)后,2例患者在接受化疗后仍有持续性疾病,3例出现复发。其中,2例出现第二次复发。在最后一次随访时,所有患者均存活,无疾病证据。接受FSS治疗的女性中也有46%(6/13)怀孕。
FSS在晚期未成熟畸胎瘤的治疗中似乎是安全有效的。尽管大多数患者接受了手术干预和化疗,但其生育结局令人满意。